Results 81 to 90 of about 1,016,101 (284)
Developing T-cell therapies for lymphoma without receptor engineering
Blood Advances, 2017 : T-cell therapy has emerged from the bench for the treatment of patients with lymphoma. Responses to T-cell therapeutics are regulated by multiple factors, including the patient's immune system status and disease stage.
Melanie Grant, Catherine M. Bollard
doaj +1 more source
Repurposing a Small Molecule Plant Hormone as a Tunable ON‐Switch for CAR‐T Cell Immunotherapy
Advanced Science, EarlyView.By engineering a receptor system integrating the plant auxin receptor AFB1 with its co‐receptor IAA7, we enable ligand‐dependent interactions triggered by the plant hormone auxins. This design allows rapid, reversible, and dose‐dependent T cell activation, resulting in potent cytotoxicity against B‐cell lymphoma in vitro and in vivo.
Hongxiang Zeng +16 more
wiley +1 more source
Chimeric antigen receptors (CARs) in cancer treatment [PDF]
, 2016 Chimeric antigen receptor (CAR) is an artificial T-lymphocyte receptor consisting of extracellular single chain antibody serving as antigen binding site, transmembrane part and intracellular part which activates the cell.
Fejtková, Martina
core
From Monoclonal Antibodies to Chimeric Antigen Receptors for the Treatment of Human Malignancies [PDF]
, 2014 Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity ...
Gianpietro Dotti +5 more
core +1 more source
Advanced Science, EarlyView.A PROTAC‐functionalized protein/DNA‐integrated nanoantigen platform is developed to enhance dendritic cell vaccine potency. By combining a VHL‐recruiting peptide‐modified antigen with a sustained expression plasmid within CaCO3 nanoparticles, this system amplifies cross‐presentation, promotes DC maturation, and elicits robust Th1 and CTL responses ...
Peng Liu +4 more
wiley +1 more source
Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
, 2019 PURPOSE The outgrowth of antigen-negative variants is a significant challenge for adoptive therapy with T cells that target a single specificity.
Rajan, Anusha +8 more
core +1 more source
Mice Transgenic for the Human Carcinoembryonic Antigen Gene Maintain Its Spatiotemporal Expression Pattern [PDF]
, 1994 The tumor marker carcinoembryonic antigen (CEA) is predominantly expressed in epithelial cells along the gastrointestinal tract and in a variety of adenocarcinomas.
Hirth, Antje +6 more
core +1 more source
IFI27 and BAX are Essential for GSDME‐Mediated Myeloma Cell Pyroptosis
Advanced Science, EarlyView.The proposed model of GSDME‐mediated MM cell pyroptosis modulated by IFI27 and BAX. IFI27 is downregulated in MM cells. Upon pyroptotic stimulation, such as DOX or ETO treatment, IFI27 is induced, therefore liberating BAX from BCL‐2 ❶. BAX is then recruited to mitochondria and forms homo‐oligomeric channels in OMM, therefore leading to cytochrome C ...
Yaoli Cui +12 more
wiley +1 more source
, 2015 A chimeric antigen receptor (CAR) comprising an extracellular spacer which comprises at least part of the extracellular domain of human low affinity nerve growth factor (LNGFR) or a derivative ...
BONINI, MARIA CHIARA +2 more
core
Engineered T Cells for glioblastoma therapy
Glioma, 2018 Engineered T cells therapy holds promise for glioblastoma (GBM) therapy. Genetic modification of T-lymphocytes, using T cell receptors, chimeric antigen receptors, and others, is an attractive antitumor strategy, especially in large solid tumors ...
Junjie Zhong, Jianhong Zhu
doaj +1 more source